GlassScriptPhysician profile
Daphne N Thomas
NPI 1770242646
$4,079.35
in general payments reported to CMS, 2019-2025
21 companies · $21.70 in 2025
The $21.70 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $863 · 2023: $1,744 · 2024: $1,451 · 2025: $21.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,216.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.05 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $477.77 | 2022-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Alkermes, INC. | $457.03 | 2022-2024 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $360.71 | 2022-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $352.61 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $285.16 | 2022-2024 | Caplyta |
| Corium, LLC | $184.77 | 2022-2024 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $172.93 | 2024 | Qelbree |
| Axsome Therapeutics, INC. | $103.75 | 2023-2024 | Auvelity, Sunosi |
| Noven Therapeutics, LLC | $92.58 | 2024 | Secuado, Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $87.55 | 2022-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $54.24 | 2022 | |
| Novo Nordisk INC | $46.33 | 2023 | Wegovy |
| Livanova USA, INC. | $36.98 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Idorsia Pharmaceuticals US INC | $34.21 | 2022-2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $34.04 | 2024 | Invega Sustenna |
| Indivior INC. | $29.60 | 2024 | Perseris |
| Neurocrine Biosciences, INC. | $28.80 | 2023 | |
| Eisai INC. | $18.91 | 2022 | |
| Lilly USA, LLC | $15.62 | 2024 | Zepbound |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.71 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daphne Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.